Cyclosporin A and bone marrow transplantation

Atkinson, K

doi:10.1007/978-94-009-0859-8_7

Cited by 4 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The meaning of cutaneous GvHD is much more complex than the verbal definition ‘graft‐versus‐host‐disease’. It is increasingly clear that abnormalities of the immunological response, characteristic of the transplant population and linked not only to the graft itself but also to the immunosuppressive therapy (ciclosporin, steroids, methotrexate), represent the substrate for the development of uncontrolled, cytotoxic responses to many different types of antigens, one of which is the CMV 42–47 …”

Section: Discussionmentioning

confidence: 99%

Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal

et al. 2004

View full text Add to dashboard Cite

show abstract

“…8 CsA is used to prevent or treat acute and chronic GVHD after allogeneic BMT; studies have shown that CsA combined with either methotrexate or steroids prevents acute GVHD and that CsA is effective in the treatment of established acute GVHD. [9][10][11][12] CsA absorption has been highly variable in BMT patients and average bioavailibility is about 30%, values ranging from 10 to 60%.…”

Section: Discussionmentioning

confidence: 99%

New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients

Parquet

Reigneau

Humbert

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Cyclosporin A (CsA) absorption is variable in bone marrow transplant (BMT) patients compromising the efficacy of graft-versus-host disease prevention. Neoral, a new microemulsion formulation of CsA which has an improved bioavailibility, increases intestinal absorption of the drug with less variable pharmacokinetic parameters in non-BMT patients. In order to predict the best dosage of Neoral when patients are switched from i.v. to oral administration we performed a randomised study comparing two oral doses, either the same or twice the last i.v. dose used after BMT. Fourteen adults were randomised around day 25 after BMT. Whole blood CSA concentrations were measured 2 and 12 h after the oral administration of Neoral on days 0, 7 and 14 to determine residual and maximum concentration, and modified whenever necessary to maintain blood level CsA concentration within therapeutic range (150-250 ng/ml). We found that patients who received twice the last i.v. dose had better concentrations than patients from the other group while toxicity was identical in both groups. We conclude that doubling the last i.v. dose during the switch to oral administration of Neoral gives the best therapeutic range concentration and should be recommended for graft-versus-host prevention. Bone Marrow Transplantation (2000) 25, 965-968. Keywords: bone marrow transplantation; cyclosporin A; pharmacokineticsIn an attempt to improve the bioavailibility of oral cyclosporin A (CsA) and to reduce variability in absorption, a new microemulsion formulation of CsA has been developed (Neoral).Pharmacokinetic studies conducted in healthy volunteers and renal, liver and cardiac transplant recipients have consistently demonstrated that absorption was increased by an average of 30% in the area-under-the-curve and was faster after Neoral than after Sandimmun. This results in an increased bioavailibility, a lower dependency on food, bile or pancreatic enzymes and a markedly reduced variability

show abstract

“…[1][2][3][4][5][6] It has been shown that CsA is effective in preventing and controlling acute and chronic GVHD in pediatric patients. 7,8 However, the use of CsA in the clinical setting is complicated by significant intrapatient and interpatient variability in its pharmacokinetics.…”

Section: Introductionmentioning

confidence: 99%

Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients

Choi

Lee

Chung

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Cyclosporin A and bone marrow transplantation

Cited by 4 publications

References 51 publications

Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal

Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal

New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients

Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients

Contact Info

Product

Resources

About